

## SCEMBLIX - Patient monitoring and management - HCP

### [Prescribing information](#)

Image



Image



 **SCEMBLIX®** ▼  
(asciminib) 20 mg, 40 mg tablets


SCEMBLIX®▼ (asciminib) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.<sup>1</sup>

## Patient monitoring and management

**Regular monitoring is important to assess treatment benefits and inform the decision to switch<sup>2,3</sup>**

Monitoring milestones of BCR-ABL1 transcript levels by the IS (international scale) at 3, 6 and 12 months is essential to determine treatment interventions.<sup>2,3</sup>

In later lines of treatment, acceptable response cannot be formally defined, but a BCR-ABL<sup>IS</sup> >1% is insufficient for optimal survival.<sup>2,3</sup>



Adapted from Hochhaus A, et al. 2020 and Smith G, et al. 2020.<sup>2,3</sup>

For full details on monitoring, please see the [ELN 2020 Guidelines](#) and the [SCEMBLIX SmPC](#).

**Even after MMR is achieved, monitoring of MMR should continue every 3-6 months<sup>2,3</sup>**

## Make monitoring and management effective

[Visit our resources pages for patient support tools](#)

BCR-ABL, breakpoint cluster region and Abelson murine leukaemia viral oncogene homologue; CCyR, complete cytogenetic remission; EMR, early molecular response; IS, international scale; MMR, major molecular response; MR, molecular response.

**For further information, please refer to the [Summary of Product Characteristics](#).**

## References:

1. SCEMBLIX (asciminib) Summary of Product Characteristics.
2. Hochhaus A, et al. *Leukemia* 2022;34:996-984.
3. Smith G, et al. *Br J Haematol* 2020;191(2):171-193.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:**

*<https://www.pro.novartis.com/uk-en/medicines/haematology/scemblix/patient-monitoring>*